Herbal Alternatives for Menopause Symptoms (HALT Study)

Vasomotor Symptoms Associated With Menopause Clinical Trial

Official title:

Herbal Alternatives for Menopause Symptoms: A Randomized Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00169299
• Other study ID #: R01AG017057
• Status: Active, not recruiting
• Phase: Phase 4
• First received: September 12, 2005
• Last updated: September 12, 2005
• Start date: June 2001
• Est. completion date: September 2004

Study information

• Verified date: September 2005
• Source: Group Health Cooperative
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Surveys indicate that 25 to 33% of women have moderate to severe menopausal symptoms including hot flashes, night sweats, and disturbed sleep. The treatment of choice in the medical community for these symptoms is hormone replacement therapy, which is estrogen and sometimes progestin. Many women also use over-the-counter herbal remedies. However, less is known about how well these products work, or their safety. Few have undergone the kind of rigorous testing required of prescription drugs and little is known about their long-term effectiveness in relieving symptoms.

The purpose of this study is to compare several over-the-counter herbal remedies to hormone replacement therapy. Our primary aim is to look at the effects of these remedies on your self-reported menopausal symptoms. We will also be measuring their effects on other factors known to be affected by hormone replacement therapy: cholesterol, blood sugar, bone density, vaginal cell structure, and blood clotting.

Description:

Hormone replacement therapy (HT: estrogen and progestin) remains the treatment of choice for women with vasomotor symptoms, and long-term HT has been recommended for prevention purposes. The demand for alternatives to HT, and the availability and use of over-the-counter products including dietary phytoestrogen supplements, and naturopathic medicines has grown dramatically. Few of these products have faced the rigors of randomized trials and none have been tested to evaluate their effects on long-term outcomes.

The purpose of this 4-year, randomized controlled trial is to evaluate the efficacy and safety of three alternative approaches utilizing phytoestrogens to treat vasomotor symptoms in peri- and postmenopausal women. The treatments were chosen because of the scientific evidence supporting a possible benefit, the availability of products with adequate quality control, their frequency of use in naturopathic medicine, and our ability to blind participants to the intervention. The 5 proposed treatment arms are: 1) conjugated equine estrogen with or without medroxyprogesterone acetate in women with or without an intact uterus respectively; 2) a single herbal product, black cohosh; 3) a multibotanical preparation; 4) a combination regimen that includes the same multibotanical preparation plus soy diet counseling; and 5) placebo. Our primary aim is to compare the effects of three alternative treatments, HRT and placebo on the frequency and intensity of vasomotor symptoms measured by The Wiklund Menopause Symptom Checklist and a daily Vasomotor Symptom Diary. Our secondary aims are to compare the effects of three alternative treatments, HRT and placebo on: 1) vaginal cytology (vaginal maturation index); 2) serum lipids (total cholesterol, HDL and LDL cholesterol, triglycerides); 3) bone mineral density (hip and spine dual energy x-ray absorptiometry scan); 4) glucose metabolism (insulin, fasting blood glucose); and 5) coagulation factors (fibrinogen, PAI-1).

Our hypotheses are that compared to placebo, the three alternative treatments tested in this proposal will; reduce frequency of hot flashes and night sweats, improve vaginal maturation and decrease vagina atrophy as measured by maturation index, lower total cholesterol and LDL with no effect on HDL, reduce the rate of decline in bone mineral density (BMD), and have no effect on glucose metabolism or clotting factors.

To accomplish our specific aims we will: 1) recruit and randomize approximately peri- and post-women to one of 5 treatment arms for one year; 2) collect measurements of primary and secondary outcomes at baseline, 3, 6, and 12 months; and 3) compare changes in outcomes in the groups taking alternative treatments to those in the HRT and placebo groups.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 351
• Est. completion date: September 2004
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 45 Years to 55 Years

Eligibility

Inclusion Criteria:

• female

• age 45 - 55

• peri- or post-menopausal

• moderate to severe vasomotor symptoms

• normal thyroid stimulating hormone

• proof of normal mammogram within past 2 years

Exclusion Criteria:

• use of HT or oral contraceptives within past 3 months

• use of herbs or alternative or complementary medicines for vasomotor symptoms within past 1 month

• medical history of contraindications to HT

• bone mineral density greater than 2 standard deviations below age specific mean

• bilateral oophorectomy

• current use of tamoxifen, raloxifene, bisphosphonates, cholesterol-lowering medications, prescription blood-thinners, or oral steroids

• pregnant or planning to become pregnant

• allergy to soybeans or soy protein

• unable to swallow pills

• current participation in another investigational drug trial

• intention to move out of area in the next 12 months

• non-compliance with procedures involved in screening and run-in trial

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Vasomotor Symptoms Associated With Menopause

Intervention

Drug:
• Black cohosh

• Multibotanical preparation

• Multibotanical preparation + dietary soy counseling

• Conjugated equine estrogen +/- medroxyprogesterone acetate

Locations

Country	Name	City	State
United States	Group Health Cooperative, Center for Health Studies	Seattle	Washington

Sponsors (3)

Lead Sponsor	Collaborator
Group Health Cooperative	National Center for Complementary and Integrative Health (NCCIH), National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Self report daily diary of frequency and intensity of vasomotor symptoms at BL, 3, 6 and 12 months.
Primary	Wiklund Menopause Symptom Checklist at BL, 3, 6 and 12 months.
Secondary	Vaginal cytology (vaginal maturation index)at BL, 3 and 12 months.
Secondary	Serum lipids (total cholesterol, HDL and LDL cholesterol, triglycerides) at BL, 3, 6, and 12 months.
Secondary	Bone mineral density (hip and spine dual energy x-ray absorptiometry scan) at BL, 6 and 12 months.
Secondary	Glucose metabolism (insulin, fasting blood glucose) at BL, 3, 6, and 12 months.
Secondary	Coagulation factors (fibrinogen, PAI-1) at BL, 3, 6, and 12 months.